Recurrent glioblastoma. C71.9
Conditions
Interventions
Intervention group: Patients diagnosed with recurrent glioblastoma meeting treatment criteria will undergo two to six cycles of Lu177-PSMA therapy. Response and side effects will be assessed after the
Sponsors
Shiraz University of Medical Sciences
Pars Isotope Company
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Glioblastoma patients who previously received standard of care therapies including surgery, radiotherapy and chemotherapy but developed with tumor recurrence or tumor progression on MRI during or after therapy. Inoperable tumors. No plan or benefit to repeat chemo or radiotherapy Sufficiently high PSMA uptake as defined >= 50% of contralateral parotid gland on Tc99m-PSMA ECOG score <=2 Consent to participate in the study
Exclusion criteria
Exclusion criteria: Pregnancy and lactation Renal failure defined as Cr>1.5 Presence of other underlying major disabilities Evidence of myelosuppression defined as WBC<3000, Hb<9 or Plt count <100000 Patients who are on previous or a new therapy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Ratio of tumor to background uptake on PSMA scan After Treatment. Timepoint: 24 hours after each cycle and 4-5 weeks after the last cycle. Method of measurement: Post -therapy Lu177-PSMA or Tc99m-PSMA SPECT/CT scan.;Overall survival and progression-free survival at 6months and 1 year after start of therapy. Timepoint: 6months and 1 year after start of therapy. Method of measurement: Patients history and follow-up.;Rate of response to therapy. Timepoint: One month after last cycle. Method of measurement: MRI.;Rate of therapy complications. Timepoint: 2 weeks and 1 month after each cycle. Method of measurement: Patient history and lab data. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAbbas Rakhsha
Shiraz University of Medical Sciences
Outcome results
None listed